Elanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study

Simply Wall St.

08/01

In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2656331360"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2656331360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2656331360?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-01 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656331360","market":"nz","top_or_hot":-1,"title":"Elanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study","media":"Simply Wall St.","content":"<div>\n<p>In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-elan-is-up-59-after-credelio-quattro-outperforms-riva\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElanco (ELAN) Is Up 5.9% After Credelio Quattro Outperforms Rivals in Tick Protection Study\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-08-01 19:30</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-elan-is-up-59-after-credelio-quattro-outperforms-riva\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-elan-is-up-59-after-credelio-quattro-outperforms-riva\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAN","symbol_name":"Elanco Animal Health Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-elan-is-up-59-after-credelio-quattro-outperforms-riva","article_id":"2656331360","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-elan-is-up-59-after-credelio-quattro-outperforms-riva","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2656331360","pubTimestamp":1785583807,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than competing products Simparica Trio and NexGard Plus, while also carrying an FDA-approved claim for Lyme disease prevention in dogs. \nAn important angle for investors is that Credelio Quattro’s rapid tick kill and Lyme prevention claim differentiate it within a crowded pet parasiticide market,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"ELAN":"Elanco Animal Health Inc"},"translate_title":"Credelio Quattro 在蜱保护研究中表现优于竞争对手，Elanco (ELAN) 股价上涨 5.9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":1.5},"content_text":"In July 2026, Elanco Animal Health reported new study results showing its Credelio Quattro chewable tablets kill black-legged and lone star ticks faster and more consistently through Day 28 than competing products Simparica Trio and NexGard Plus, while also carrying an FDA-approved claim for Lyme disease prevention in dogs.  An important angle for investors is that Credelio Quattro’s rapid tick kill and Lyme prevention claim differentiate it within a crowded pet parasiticide market, potentially strengthening Elanco’s broader innovation-focused portfolio.  We’ll now assess how Credelio Quattro’s faster, sustained tick kill profile could influence Elanco’s existing investment narrative around innovation-led growth. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementElanco Animal Health Investment Narrative RecapTo own Elanco, you need to believe its innovation engine in pet and farm animal health can translate into profitable growth while it manages debt and spending. The new Credelio Quattro tick-speed data reinforces that innovation story and could support near term uptake, but the key near term catalyst remains execution on launches like Zenrelia and Credelio Quattro themselves. The biggest risk is that adoption and clinic penetration fall short of expectations, leaving margins and deleveraging under pressure. Among recent announcements, the 2025 「Leading with Purpose」 Impact Report ties directly into this. It highlights Elanco’s intent to secure 5 to 6 potential blockbuster approvals by 2031, with Credelio Quattro clearly positioned as one of the early test cases. How well Credelio Quattro converts differentiated clinical data into real world demand will be an important proof point for that broader innovation focused story. Yet while Credelio Quattro’s profile looks promising, investors should also be aware that... Read the full narrative on Elanco Animal Health (it's free!)Elanco Animal Health's narrative projects $5.6 billion revenue and $247.5 million earnings by 2029. This requires 4.8% yearly revenue growth and a $489.5 million earnings increase from -$242.0 million today.Uncover how Elanco Animal Health's forecasts yield a $29.79 fair value, a 13% upside to its current price.Exploring Other PerspectivesELAN 1-Year Stock Price Chart Some of the most optimistic analysts were already modeling revenue near US$5.8 billion and earnings around US$454 million by 2029, so this kind of data may strengthen their innovation driven view, but you should weigh that against the risk that elevated debt still constrains Elanco’s flexibility and consider how your own expectations compare to those more bullish forecasts.Explore 3 other fair value estimates on Elanco Animal Health - why the stock might be worth just $26.82!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Elanco Animal Health research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Elanco Animal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elanco Animal Health's overall financial health at a glance.Seeking Other Investments?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Find 55 companies with promising cash flow potential yet trading below their fair value.We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elanco Animal Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}